Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Announces Second Quarter 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Announces First Quarter 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Provides Regulatory Update for SPN-830
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Announces Third Quarter 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus to Participate in the Jefferies London Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Supernus to Participate in the Wells Fargo Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Bethany L. Sensenig Joins Supernus’ Board of Directors
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.